Release date: 5 September 2017
Promoter – Financial IntermediaryHUVEPHARMA INTERNATIONAL BV
The project consists of the construction of new manufacturing facilities, as well as financing of the promoter's research, development and innovation (RDI) activities.
The EIB loan will be supporting the capacity expansion of a mid-cap company in Bulgaria.
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 125 million
Total cost (Approximate amount)
EUR 212 million
The project falls under Annex II of EIA Directive 2011/92/EU (implementation of an industrial facility for the production of pharmaceutical products). Full environmental details will be assessed during the appraisal.
The promoter is a private company not operating in the utilities sector and is thus not covered by EU directives on procurement.
Signed - 22/12/2017
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).